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ABSTRACT 
 This study examined the influence of lactation, and choline intake during lactation, on 
biomarkers of choline metabolism.  Lactating (n=27) and control (n=21) women were 
randomized to 480 or 930mg choline/d for 10-12 wks; Blood and urine were collected for 
choline metabolite (and enrichment) measurements while blood leukocytes and mammary 
epithelium were collected for gene expression analysis of choline metabolic genes.  Lactating 
(vs. control) women exhibited elevated plasma choline and betaine; decreased urinary 
excretion of betaine and dimethylglycine; and increased leukocyte transcript abundance of 
CHDH.  A higher choline intake by lactating women yielded higher plasma betaine and 
dimethylglycine, higher serum sarcosine, and higher milk glycine.  These data collectively 
suggest that lactation induces metabolic adaptations to increase the supply of betaine perhaps 
secondary to its role as an osmolyte, and that extra choline during pregnancy increases 
metabolites that may be important in milk synthesis.  
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INTRODUCTION 
Choline is an essential water-soluble micronutrient with adequate intake (AI) 
recommendations of 425 mg/d for adult women, 450 mg/d for pregnant women, and 550 mg/d 
for lactating women (IOM 1998). Choline functions in the body as the precursor molecule for an 
array of metabolites with critical roles in human health (see Figure 1).  Derivatives of choline 
include the cell membrane and lipoprotein constituent, phosphatidylcholine (PC); the methyl 
donor betaine; and the cholinergic neurotransmitter acetylcholine.  PC biosynthesis can occur 
through one of two pathways: (i) the cytidine diphosphate-choline (CDP-choline) pathway in 
which free choline is phosphorylated and then attached to diacylglycerol; or (ii) the 
phosphatidylethanolamine N-methyltransferase (PEMT) de novo pathway involving the S-
adenosylmethionine (SAM)-dependent sequential tri-methylation of phosphatidylethanolamine 
(PE) to PC.  Although considered a route of de novo choline synthesis, choline itself can serve as 
a source of methyl groups for the methylation of PE to PC (Yan et al., 2011) and thus PEMT 
activity is influenced by choline supply (Yan et al. 2011, West et al. 2013).  Betaine is the 
oxidized derivative of choline and is a major source of methyl groups (Zeisel et al., 2003), but 
also a potent osmolyte (Lever and Slow, 2010). Methyl donation by betaine remethylates 
homocysteine to methionine and generates dimethylglycine (DMG), methylglycine (sarcosine), 
and glycine in a sequential demethylation manner as follows: betaine → DMG → sarcosine → 
glycine.  
 The vital role of choline and its high demand in human development are increasingly 
recognized (Zeisel, 2013; Nyaradi et al., 2013; Boeke et al., 2013; Caudill, 2010).  Human 
pregnancy has a profound effect on choline metabolism.  Pregnant (vs. control) women exhibit 
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diminished plasma concentrations of choline derived methyl donors (Yan et al., 2012; Friesen et 
al., 2007) and increased obligatory losses of choline metabolites (Yan et al., 2012).  In addition, 
a higher maternal choline intake during pregnancy may improve maternal and child health 
outcomes. Supplementing the diet of third trimester pregnant women with extra choline has 
been shown to: (i) decrease the placental production of sFLT1, an anti-angiogenic factor that 
increases the risk of placental dysfunction and preeclampsia (Jiang et al., 2013); and (ii) 
attenuate fetal response to stress by altering the methylation, and expression, patterns of 
genes that regulate fetal cortisol production (Jiang et al., 2012).  Further, rodent studies have 
consistently demonstrated lasting beneficial effects of perinatal choline supplementation on 
offspring cognitive functioning (Corriveau et al., 2012; Monk et al., 2012; Williams et al., 1998; 
Jones et al., 1999; Pyapali et al., 1998; Montoya et al., 2000; Meck et al., 1997a; Meck et al., 
1997b; Meck et al., 1999; Meck et al., 1993).   
Less is known about the influence of lactation, and choline intake during lactation, on 
choline metabolism. However, substantial amounts of choline are present in human milk 
(Holmes-McNary et al., 1996) and lactation has been shown to deplete liver choline stores in 
rodents on a normal feed-pellet diet (Zeisel et al., 1995), indicating that PEMT activity is 
insufficient to meet choline demands during lactation. In addition, milk choline corresponds to 
dietary choline intake in lactating rats (Holmes-McNary et al., 1996) and with biomarkers of 
maternal choline metabolism in humans (Ilcol et al., 2005). Further, supplementation of the 
maternal diet with additional choline in the form of PC improves milk choline content (Fischer 
et al., 2010), which may be important for infant cognition (Aizawa et al., 2011).  
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To further understanding of the impact of lactation, and choline intake during lactation, 
on choline metabolism and dietary requirements, we conducted a dose-response feeding study 
in lactating and control women.  A comprehensive panel of choline metabolites in maternal 
blood and urine were quantified together with the transcript abundance of several choline 
metabolizing enzymes in maternal leukocytes and the mammary epithelium.  In addition, stable 
isotope methodology was employed to determine the metabolic flux and partitioning of choline 
and its methyl groups among choline-related metabolic pathways. Deuterium methyl-d9-
choline was used as the tracer and has three deuterium labels on each of choline’s three methyl 
groups (see Figure 1).  Measuring the enrichment of choline metabolites enables the tracing of 
the intact molecule (d9 species) and its methyl groups (d3- or d6- species).     
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FIGURE 1. Choline metabolism and the metabolic fate of orally consumed deuterium-labeled 
choline. The d9-choline tracer (see top right) contained deuterium-labeled methyl groups 
thereby facilitating examination of the metabolic fate of choline-derived methyl groups in 
addition to the intact molecule. During methyl donation, d9-choline may be oxidized to d9-
betaine, followed by conversion of d9-betaine to d6-dimethylglycine and donation of a labeled 
methyl group containing three deuterium labels to methionine. These donated labeled methyl 
groups may be used to produce d3 or d6-PC through the PEMT pathway. PEMT-PC labeled with 
one (d3-PC) or two (d6-PC) methyl groups may then be metabolized to form free choline 
resulting in d3-choline. d3-choline may be oxidized to d3-betaine, followed by another round of 
methyl donation. Alternatively, intact dietary choline containing all of its original methyl groups 
(d9-choline) may proceed down the CDP-choline pathway to produce d9-PC without entering 
methyl donation. Circles, methyl groups; grey circles, labeled methyl groups; white circles, 
unlabeled methyl groups.  
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METHODS 
Study participants 
 Healthy lactating (5-wk postpartum) and control women (non-pregnant, non-lactating) 
aged 21-41 y were recruited from Ithaca, NY, and surrounding areas between January 2009 and 
October 2010 (West et al 2012.; Yan et al. 2012). Entry into the study was contingent on good 
health status as assessed by a blood chemistry proﬁle, complete blood count, and medical 
history questionnaire. Additional inclusion criteria included no tobacco or alcohol use, no 
history of chronic disease, normal kidney and liver function, and a willingness to comply with 
the study protocol.  For lactating women, this included the intention to exclusively breastfeed 
for the duration of the study. Exclusion criteria included the use of prescription medications 
known to affect liver function.  The screening and experimental procedures were approved by 
the Institutional Review Boards for Human Participants at Cornell University and Cayuga 
Medical Center, and written informed consent was obtained prior to study entry. The study was 
registered at ClinicalTrials.gov as NCT01127022 (http://clinicaltrails.gov/) and the Consort 
ﬂowchart has been reported (Yan et al., 2012).  
 
Study design, diet and supplements 
 This was a dose-response feeding study in which lactating (n=28) and control (n=21) 
women were randomized to either 480 mg choline/d (n=15 lactating, n=10 control) or 930 mg 
choline/d (n= 13 lactating, n=11 control) for 10-12 weeks, as described previously (Yan et al., 
2012). Our control cohort is the same group of women that served as the reference group for 
our prior study examining the effect of pregnancy on choline intake (Yan et al., 2012).  
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However, in the present study, biomarkers of choline metabolism in the control cohort were re-
measured concurrently with measurements in our lactating cohort to ensure internal validity. 
Choline was derived from the study diet (380 mg/d) plus supplemental choline chloride (either 
100 or 550 mg choline/d) for total choline intakes of 480 or 930 mg/d, respectively. During the 
last 4-6 wks of the study, participants consumed 22% of their total choline intake (480 or 930 
mg choline/d) as methyl-d9-choline. 
Throughout the 10-12 wk study, participants consumed a 7-d cyclic menu (Yan et al. 
2012). All food items and beverages were provided by the investigators, and one meal/d was 
consumed on-site throughout the week. All other meals and beverages were provided as 
takeaways. In addition to the supplemental choline chloride (Balchem, New Hampton, NY, 
USA), study participants consumed a daily 200mg docosahexaenoic acid supplement 
(Neuromins; Nature’s Way Products, Springville, UT, USA), a daily over-the counter choline free 
prenatal multivitamin supplement (Pregnancy Plus;  Fairhaven Health, LLC, Bellingham, WA, 
USA), and a thrice-weekly  potassium/magnesium supplement (General Nutrition Corp., 
Pittsburgh, PA, USA) in order to achieve recommended nutrient intake levels not met with the 
study diet (Yan et al. 2012). When eating on site, participants consumed supplements under the 
supervision of study personnel. Otherwise, supplements were provided in plastic bags along 
with takeaway meals, and participants were instructed to consume the supplements with a 
meal of their choice. Consumption of each menu and supplement item was verified through the 
use of a daily checklist provided by the investigators. 
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Sample collection and processing   
  Fasting blood samples were collected into serum separator gel and clot activator tubes 
(SST Vacutainer, Becton, Dickinson and Company) and EDTA coated tubes (Vacutainer) at study 
baseline (wk 0), study midpoint (wk 6), wk 9, and study-end (wk10) (defined as wk 10 for both 
lactating and control women). Blood samples were processed for plasma, serum, and buffy coat 
as previously described (Yan et al. 2012). 24 hr urine samples were collected throughout the 10 
wk study, processed, and stored at -80°C (Yan et al., 2012). Breastmilk was expressed in the 
morning at the Human Metabolic Research Unit (HMRU) by pumping with a Medela electric 
breast pump (Medela Inc). Lactating women were fasted for breastmilk sample collection that 
occurred on the same morning as the corresponding week’s blood collection. Breastmilk 
samples consisted of the full expression of one breast 2 hr after the first feed of the day. 
Women expressed the same breast throughout the study. On collection, breastmilk samples 
were immediately placed on ice, dispensed into 15 mL centrifuge tubes, and stored at -80C. 
      
Extraction of RNA from buffy coat and mammary epithelium  
 Total RNA was extracted from blood leukocytes via a commercially available kit (RNeasy 
Mini kit; Qiagen) at the time of blood processing and stored at -80°C. DNase treatment (Turbo 
DNA-free DNase; Ambion) of leukocyte RNA was performed according to the manufacturer’s 
protocol to remove genomic DNA contamination. Mammary epithelium total RNA was isolated 
from the breastmilk at the time of milk processing by a modification of the Trizol method 
(Simms et al., 1993). Briefly, breastmilk (15 mL) was centrifuged at 2000g for 10 min at 4°C and 
the fat layer was collected from the top of the tube and homogenized with 1.5ml Trizol. The 
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homogenized samples were vortexed with 200 ul chloroform and centrifuged at 12000rpm for 
15 min at 4°C. The clear aqueous phase was subsequently removed and mixed with 0.75 ml 
isopropanol in a new tube. Tubes were inverted repeatedly and then incubated at room 
temperature for 30 min. Centrifugation was repeated at 12000 rpm for 15 min at 4°C. The 
supernatant was removed by pipetting and the RNA pellet at the bottom of the tube was 
washed with 1 ml 75% ice cold ethanol. Tubes were centrifuged again at 12000 rpm for 5 min at 
4°C, and the supernatant was removed. Finally, the RNA pellet was resuspended in 50 ul of 
RNase free water and stored at -80°C.   
RNA concentrations for both blood leukocytes and mammary epithelium were 
measured via Nanodrop (NanoDrop™ ND1000 Spectrophotometer, Thermo Scientific). Samples 
with a 260/230 ratio >1.8 were considered to have sufficiently pure RNA for assessment of 
transcript abundance. 
 
cDNA production  
 Reverse transcription of blood leukocyte and mammary epithelium total RNA was 
performed on a MyCycler thermocycler (BioRad). For reverse transcription, RNA  (2.5 µg)  was 
pipetted into a PCR tube with 1.83 µl of RNase free water and subsequently incubated at 70°C 
for 10 min and 4°C for 5 min. The remainder of reverse transcription was performed via the 
ImProm-II Reverse Transcription System (Promega, Madison, WI, USA). The reaction conditions 
were as follows: 25°C for 10 min; 42°C for 40 min; 95°C for 5 min, and quenching at 4°C for 5 
min. Following reverse transcription, leukocyte cDNA was diluted 1/15 and mammary 
epithelium cDNA was diluted 1/5 based on prior RNA concentrations and stored at -80°C.  
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QPCR measurement of choline metabolism gene expression  
 Quantitative real-time PCR (qPCR) analysis was performed on a Lightcycler 480 II 
(Roche). Genes of interest in blood leukocytes and mammary epithelium included 
phosphocholine cytidyl transferase (PCYT1A), acetylcholinesterase (ACHE), acetylcholine 
muscarinic receptor (CHRM4), choline dehydrogenase (CHDH), and phosphatidylethanolamine 
N-methyltransferase (PEMT). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as 
the housekeeping gene for both blood leukocytes and mammary epithelium. All primers were 
designed using GeneRunner 3.01 (http://www.softpedia.com/). Primers were as follows: 
GAPDH, forward, 5’-CTCCACGACGTACTCAGCG-3’, and reverse, 5’-TGTTGCCATCAATGACCCCTT-
3’; CHRM4, forward, 5’-TGTGCTGATCTCATCATAGGC-3’, and reverse, 5’-
TCACCACGTAGTCCAGGGC-3’; PEMT, forward, 5’-GGGGTTCGCTGGAACTTTC-3’, and reverse 5’-
GCCCAGGTAGTTGGCTGTG-3’; PCYT1A, forward, 5’-CAGAAGGTGGAGGAAAAAAGCA-3’, and 
reverse, 5’-TATGTTTCAGTGCTCCTTCCGG-3’; ACHE, forward, 5’-CGCTACAACCTTCCAGAGTG-3’ 
and reverse 5’-ACACGTTGAGGTACAGGCAG-3’; CHDH, forward, 5’-
GCAAGGAGGTGATTCTGAGTGG -3’ and reverse 5’- GGATGCCCAGTTTCTTGAGGTC-3’;. The 
quality of primers was assessed by the consistency, height, and tightness of the melting curves.  
Blood leukocyte derived cDNA was analyzed with the Roche SYBR Green system. The program 
for leukocyte analysis was as follows: preheat at 95°C for 5 min; amplification phase was 95°C 
for 30 sec, 60C for 30 sec, and 72°C for 30 sec, for a total of 45 cycles. Mammary epithelium 
derived cDNA was analyzed with the Maxima SYBR Green system (Fermentas). The program for 
mammary epithelium analysis was as follows: preheat 95°C for 10 min; amplification phase was 
95°C for 15 sec, 60°C for 30 sec, and 72°C for 30 sec, for a total of 45 cycles. Data were 
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expressed by the delta delta Ct method, in which the expression level of the gene of interest 
was normalized by the expression level of the housekeeping gene as fold change before 
comparison between samples (Livak and Schmittgen, 2001).  
 
Genotyping 
  Select genetic variants were ascertained in one-carbon metabolic genes that may 
impact choline metabolism, including betaine-homocysteine N-methyltransferase (BHMT) 
G742A (rs3733890), choline dehydrogenase (CHDH) G233T (rs12676), 
methylenetetrahydrofolate dehydrogenase 1 (MTHFD1) G1958A (rs2236225), 
methylenetetrahydrofolate reductase (MTHFR) C677T (rs1801133), phosphate 
cytidylyltransferase 1, choline, α (PCYT1A) (rs939883, T→A),5-methyltetradhydrofolate-
homocysteine methyltransferase (MTR) A2756G (rs1805087), 5-methyltetrahydrofolate-
homocysteine methyltransferase reductase (MTRR) A66G (rs1801394), and PEMT G5465A 
(rs7946). BHMT G742A, MTHFD1 G1958A, and MTHFR C677T polymorphisms were determined 
by sequencing the double-stranded DNA templates with an Applied Biosystems Automated 
3730 DNA analyzer. All other genotypes were determined using fluorescent TaqMan probe 
commercially available kits (Applied Biosystems, Foster City, CA).  
 
Measurements of plasma and urine choline metabolites 
 Phosphatidylcholine (PC) and sphingomyelin (SM) were extracted from plasma (study 
wks 0, 6, 9, and 10), along with the PC and SM isotopomers (d0, d3, d6 and d9), and 
subsequently quantified by liquid chromatography-tandem mass spectrometry (LC-MS) 
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according to the method of Koc et al. (Koc et al., 2012). The Koc et al. method was modified by 
our lab by using d4-PC, rather than d9-PC, as the internal standard (Yan et al., 2011). Ions with a 
m/z ratio of 184 were monitored for unlabeled metabolites (d0-PC and d0-SM), ions with a m/z  
ratio of 188 were monitored for d4-PC, and ions with m/z ratios of 187, 190, and 193 were 
monitored for d3 labeled metabolites (d3-PC and d3-SM), d6 labeled metabolites (d6-PC and 
d6-SM), and d9 labeled metabolites (d9-PC and d9-SM), respectively. Because the d4-PC 
internal standard yielded ions with m/z ratios of 188 (the ions monitored for d4-PC) and 190 
(the ions monitored for d6-PC), a second run without the addition of d4-PC was conducted for 
plasma at study wks 9 and 10. The second run was used to determine enrichments of the PC 
isotopomers (i.e., d3-PC divided by the sum of d3-, d6- and d9-PC).  
 Free choline, betaine, and dimethylglycine (DMG) were extracted from plasma (study 
wks 0, 6, 9, and 10) and urine (study wks 0, 6, 9, 10). The isotopomers of these metabolites (d0, 
d3, d6 and d9) were quantified by LC-MS/MS according to the method of Holm et al. (Holm et 
al., 2003) with modifications including the use of d13-choline, d3-betaine, and d3-DMG, rather 
than d9-choline, d9-betaine, and d6-DMG, as internal standards. The ions with m/z ratios 
monitored for each metabolite were as follows: d0-choline, 104 → 60; d3-choline, 107 → 63; 
d6-choline, 110 → 66; d9-choline, 113 → 69; d13-choline, 117 → 69; d0-betaine, 118 → 59; d3-
betaine 121 → 62; d6- betaine, 124→ 65; d9-betaine, 127 → 68; d0-DMG, 104 → 58; d3-DMG, 
107 → 61; d6-DMG, 110 → 64. As the internal standards, d3-betaine and d3-DMG were also 
target metabolites for quantification, a separate run without the addition of internal standards 
was conducted to measure plasma and urine enrichments (as described above). Urine data are 
reported as total metabolite excreted, not as a concentration.   
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 For analysis of choline metabolite abundance at wks 9 and 10, given that a percentage 
of the choline supplied was deuterium labeled, the deuterium label (d3,d6,d9) areas  were 
combined with the unlabeled metabolite areas to calculate total metabolite abundance.  
 
Measurements of plasma and urine amino acid metabolites  
  Homocysteine, cysteine, methionine, cystathionine, glycine, and sarcosine were 
extracted from serum (study wks 0, 6, and 10) and urine (study wks 0, 6, and 10). Gas 
chromatography-mass spectrometry (Stabler et al., 1987; Allen et al., 1993) was employed to 
quantify these amino acids.  Urine data are reported as total metabolite excreted per 24-h, not 
as a concentration.   
 
Isotopic enrichment calculations  
 Isotopic enrichment [labeled metabolite/(labeled + unlabeled metabolites)] was 
examined in blood and urine to monitor the flow of dietary choline (d9-choline metabolites) 
and its methyl groups (d3 and d6-choline metabolites) through the choline metabolic pathways. 
The isotopic enrichment percentage was calculated using the peak area under the 
chromatography curve of the labeled metabolite divided by the total area under the curve of all 
isotopomers of the metabolite. For example, d3-PC enrichment = peak area of d3-PC / peak 
area of (d0+d3+d6+d9)-PC × 100%. The enrichment of d3-PC indicates the proportion of PEMT-
derived d3-PC in the total plasma PC pool. Metabolite enrichment ratios were examined as 
indicators of the flow of orally consumed choline through a specific portion of a pathway (i.e., 
enrichment of product/ enrichment of precursor) or its partitioning between pathways (e.g., 
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CDP-choline pathways, choline oxidative pathway). Under the current labeling strategy, the 
amount of PEMT-derived d9-PC (~ 0.02% of plasma total PC) was lower than the detection 
limits (~ 0.1% of plasma total PC). Therefore, we assumed that all of the measured d9-PC was 
derived from the CDP-choline pathway. 
 
Statistical Analysis  
 Plots and histograms of the residuals were used to assess normality and variance 
homogeneity. Data that deviated from the normal distribution were logarithmically 
transformed to achieve normality, and the transformed data were used in subsequent analyses. 
The presence of outliers within the data set was also assessed using box plots; values >3x the 
interquartile range of the boxplot of the data were excluded.  
To test for baseline (wk 0) differences in the continuous variables, a two-factor ANOVA 
(choline intake, lactation, and their interaction) was performed, or in cases where variables 
were only available for lactating women, a one-factor ANOVA (choline intake) was conducted.  
To test for baseline (wk 0) differences in the categorical variables (e.g., genotype frequency, 
ethnicity, education) between lactating and control women and choline intake groups,  chi-
square tests, or when expected counts were less than five, Fisher’s exact tests, were used.  
 To delineate the impact of reproductive state on the dependent variables (i.e. choline 
metabolite concentrations) through time, a mixed linear model (MLM) was constructed for 
each dependent variable. As lactation is a physiologic state, not a treatment, baseline (week 0) 
measures of dependent variables were included as a data point. Reproductive state, continuous 
time (e.g., wks 0, 6, 9, and 10 for plasma variables; wks 0, 6, and 10 for urine/serum variables), 
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choline intake, and their interactions were included as ﬁxed effects; the sample identiﬁer was 
included as a random effect.  
To delineate the impact of choline intake on the dependent variables (i.e., choline 
metabolite concentrations and amino acid metabolite concentrations) among lactating women, 
a MLM was constructed for each dependent variable. As baseline (wk 0) measures may 
inﬂuence the response to choline treatment, measures of the dependent variables at wk 0 were 
included as a covariate. Choline intake, continuous time (e.g., wks 6, 9, and 10 for plasma 
variables; wks 6 and 10 for urine/serum variables), and their interaction were included as ﬁxed 
effects; the sample identiﬁer was included as a random effect; and the week 0 measure was 
included as a covariate.  
 To test for differences in mRNA abundance based on reproductive state in blood 
leukocytes, a 2-factor ANOVA (choline intake and lactation) was performed with the study-end 
(wk10) mRNA abundance as the dependent variable and choline intake, lactation, and their 
interaction as independent variables. To test for differences in mRNA abundance based on 
choline intake in blood leukocytes and mammary epithelium of lactating women only, a one-
factor ANOVA (choline intake) was performed with the study-end (wk10) mRNA abundance as 
the dependent variable and choline intake as the independent variable; baseline mRNA 
abundance (wk0) was included as a covariate. Pearson’s correlation analysis of the mRNA 
expression of choline metabolism genes in blood leukocytes of lactating women at study-end 
(wk10) versus the mRNA expression of the same genes in mammary epithelium at study-end 
(wk10) was also performed. 
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 Finally, to test for differences in choline metabolite enrichment based on reproductive 
state in urine and plasma, a 2-factor ANOVA (choline intake and lactation) was performed with 
the study-end (wk10) choline metabolite enrichment as the dependent variable and choline 
intake, lactation, and their interaction as independent variables. To test for differences in 
choline metabolite enrichment based on choline intake in plasma and urine of lactating women 
only, a one-factor ANOVA (choline intake) was performed with the study-end (wk10) choline 
metabolite enrichment as the dependent variable and choline intake as the independent 
variable. Baseline enrichment (wk 0) was not included as a covariate because deuterium-
labeled choline metabolites were not present.  
 Candidates for entry as additional covariates into all MLMs and ANOVAs were age, BMI, 
ethnicity, and the eight genetic variants in one-carbon metabolic genes. In addition, where 
possible, genotypes with a count of ≤2 at a given loci were combined together with the 
heterozygote genotype to yield samples sizes of ≥3 for each genotype in the model (all 
genotypes were combined in this manner except for PCYT1A (rs939883, T→A), MTHFD1 
G1958A (rs2236225), and MTRR A66G (rs1801394)). The covariates that did not achieve a 
signiﬁcance of (P<0.1) were removed from the models in a stepwise manner.  
All analyses were performed using SPSS 21.0 for Windows (SPSS Inc, Chicago, IL, USA). 
Differences were considered to be signiﬁcant at values of P≤0.05 and P≤0.10 was considered to 
be indicative of trends. Values are presented as means ± standard error unless noted 
otherwise. 
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RESULTS 
Participant Characteristics and Baseline Measures 
 Forty-eight women were included in the final analysis:  21 control women who 
completed 10 wks of the study and 27 lactating women who completed 10 wks (n=25) or 9-wks 
(n=2) of the study.  Data were available for every time point (wks 0, 6, and 10 for serum; wks 
0,6,9, and 10 for urine; wks 0, 6, 9, and 10 for plasma; and wks 0 and 10 or wks 0 and 9 for 
mRNA abundance) with the exception of those who ended the study early at wk9 (missing wk 
10),  three wk 9 plasma samples, one wk 10 sample for urine only, and 8 RNA wk0-wk10 pairs (7 
blood leukocyte, 1 mammary epithelium) which were of insufficient quantity or poor quality  
 At baseline, lactating (vs. control) women used less (p=0.0001) oral contraception, 
consumed more (p=0.005) vitamin supplements, were less (p=0.04) physically active, and 
differed in the frequency of the PEMT (P=0.03) and PCYT1A (P=0.03) genotypes (see Table 1).  
Lactating (vs control) women also exhibited lower (p=0.01) leukocyte PEMT mRNA abundance, 
higher (p=0.001) leukocyte CHDH mRNA, lower (p=0.001) leukocyte CHRM4 mRNA abundance, 
higher (p=0.0001) plasma choline, and excreted less urinary betaine (p=0.0001) and DMG 
(p=0.0001) (Table 1).  Otherwise, the dependent variables of interest did not differ between the 
reproductive groups (Table 1). For choline intake, no differences at baseline were detected 
between the 930 and 480 mg choline/d intake groups for any of the dependent variables (data 
not shown) with the exception of plasma choline which was lower (p=0.02) in the 930 (6.3 ± 1.5 
nM/mL) vs. 480 (7.3  ±  1.7 nM/mL) mg/d group.  In addition, no interactions (P> 0.1) were 
detected between reproductive state and choline intake assignment for any of the dependent 
variables.  
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TABLE 1. Baseline characteristics, mRNA abundance, and metabolite concentrations in control 
and lactating women. 1 
Variables 
Control Women Lactating Women P Value 
Characteristics2 
Ethnicity  
(Caucasian/African/ 
Latino/Asian/Other) 14/2/2/1/2 19/1/3/1/3 1  
Age (yrs) 28.8 (21-40) 29.1 (22-41) 0.8 
Prepregnancy BMI 23.6 (18-30) 26.7 (18-42) 0.1 
Education  
(high school/associate/ 
bachelors/masters/ doctorate/other) 6/0/5/5/5/0 7/3/10/7/0/1 0.06 
Oral Contraceptive Use (no/yes) 12/9 27/1 0.001 
Vitamin Supplement Use (no/yes) 14/7 7/20 0.005 
Physical Activity (low/medium/high) 3/10/8 12/13/3 0.04 
Genotypes (counts) 
MTHFR, rs1801133, 677 (CC/CT/TT) 9/9/3 11/15/1 0.5 
MTHFD1, rs2236225, 1958 
(GG/GA/AA) 3/15/3 6/17/4 0.9 
BHMT, rs3733890, 742 
(GG/GA/AA/unknown) 13/7/1/0 7/12/4/4 0.1 
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PEMT, rs7946, 5465 (GG/GA/AA) 5/10/6 4/5/18 0.03 
CHDH, rs12676,  233 (GG/GT/TT) 12/7/2 16/9/2 1 
PCYT1A,  rs939883,  
(TT/TA/AA) 9/9/3 5/21/1 0.03 
MTR, rs1805087, 2756 (AA/GA/GG) 14/6/1 18/9/0 0.7 
MTRR, rs1801394, 66 (AA/GA/GG) 7/9/5 9/13/5 0.9 
Blood Leukocyte mRNA expression (fold mRNA abundance relative to control women)3 
ACHE 1 ± 1.2 0.5 ± 1.1 0.3 
PEMT 1 ± 1.2 0.1 ± 0.1 0.01 
PCYT1A 1 ± 1.3 0.4 ± 0.2 0.5 
CHDH 1 ± 0.6 2 ± 1 0.001 
CHRM4 1 ± 1.5 0.2 ± 0.1 0.001 
Mammary Epithelium mRNA expression (fold mRNA abundance relative to GAPDH)4 
PEMT 
 
1.3 ± 0.1 
 PCYT1A 
 
1.3 ± 0.1 
 CHDH 
 
1.4 ± 0.1 
 Plasma Choline Metabolite Concentrations5   
Choline (nM/mL) 5.9 ± 1.6 7.5 ± 1.4 0.0001 
Betaine (nM/mL) 25 ± 10 27 ± 8 0.5 
Dimethylglycine (nM/mL) 2.4 ± 2 1.9 ± 0.6 0.3 
Phosphatidylcholine (nM/mL) 1586 ± 301 1652 ± 372 0.6 
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Sphingomyelin (nM/mL) 509  ± 92 551 ± 114 0.2 
Urinary Choline Metabolite Excretion5 
Choline ( mg/d)  2.5 ± 1.1 2.4  ± 0.9 0.9 
Betaine (mg/d) 8.8  ± 5.6 3.9  ± 2.5 0.0001 
Dimethylglycine (mg/d) 3.7  ± 2.2 1.6  ± 1.3 0.0001 
Serum Amino Acids5 
Methionine (uM/mL) 
 
25 ±  4.2 
 Cysteine (uM/mL) 
 
296 ±  33 
 Homocysteine (uM/mL) 
 
6.2 ±  1 
 Glycine (uM/mL) 
 
348 ±  76 
 Sarcosine (uM/mL) 
 
1.2 ±  0.3 
 Cystathionine (nM/mL) 
 
157 ±  96 
 Urinary Amino Acid Excretion5 
Methionine (g/d) 
 
1.5 ± 0.9 
 Cysteine (g/d) 
 
28 ± 8.8 
 Homocysteine ( g/d) 
 
0.4 ± 0.1 
 Glycine (g/d) 
 
95 ± 54 
 Sarcosine (g/d) 
 
0.32 ± 0.2 
 Cystathionine (mg/d) 
 
2.2 ± 1.6 
 1 Continuous variables were analyzed using 2-factor ANOVA (i.e., choline and lactating state as 
independent factors) or 1-factor ANOVA (i.e., choline intake in lactating women as the 
independent factor); chi-square or Fishers exact test was used to analyze categorical variables.  
Sample size was n=21-27 per reproductive group (unless noted otherwise) and n=10-14 per 
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choline intake group.  No differences were detected between choline intake groups within a 
reproductive category (data not shown) with the exception of plasma choline which was lower 
(p=0.024) in the 930 (6.3 ± 1.5 nM/mL) vs. 480 (7.3  ±  1.7 nM/mL) mg/d group. Data are not 
stratified by choline intake because reproductive state and choline intake did not interact to 
affect the dependent variables. 
2 Mean, (range in parenthesis), or spread of data 
3 Arithmetic mean fold mRNA abundance ± standard deviation; n=16-27 per reproductive 
group. mRNA abundance calculated as fold change  relative to control women.   
4 Arithmetic mean fold mRNA abundance ± standard deviation. mRNA abundance calculated as 
fold change relative to housekeeping gene, GAPDH. 
5 Arithmetic means ± standard deviation.  
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Effect of Reproductive State on Biomarkers of Choline Metabolism 
Blood leukocyte choline metabolic gene expression    
 At study-end (wk10), lactating vs. control women exhibited lower ACHE (p=0.0001) and 
CHRM4 (p=0.04) expression and tended to have higher (p=0.01) CHDH expression (see Table 2).  
Expression of PEMT and PCYT1A was unchanged.  As there were no significant interactions 
between choline intake and lactation, reproductive groups were not stratified by choline intake 
and reanalyzed.  
  
TABLE 2. Effect of reproductive state on mRNA abundance at study-end (wk10).  1-3 
 
Genes Control Women Lactating Women P value 
ACHE 1  ± 1.3 0.2 ± 0.3 0.0001 
PEMT 1  ± 1.9 0.3  ±  0.3 0.1 
PCYT1A 1  ± 1.2 0.5  ± 0.2 0.4 
CHDH 1  ± 0.6 1.4  ± 0.7 0.1 
CHRM4 1  ± 1.4 0.4  ±  0.2 0.04 
1 Arthimetic mean ± standard deviation; n=16 for control women, n=24-27 for lactating women   
2 Data are presented as fold change using control women as the reference (e.g. lactating 
women average value / control women average value) and were analyzed by 2-factor ANOVA.  
Data are not stratified by choline intake because reproductive state and choline intake did not 
interact to affect the dependent variables.  
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Plasma choline metabolite concentrations   
 Throughout the study period, lactating (versus control) women exhibited higher plasma 
concentrations of choline (p=0.001) and betaine (p=0.03); whereas plasma concentrations of 
dimethylglycine, phosphatidylcholine, and sphingomyelin were not influenced by reproductive 
state (see Table 3). In addition, no interactions were detected between reproductive state and 
choline intake (P≥0.1) or time (P≥0.3). 
 
TABLE 3. Effect of reproductive state on plasma choline metabolite concentrations across the 
study period. 1,2 
 
Metabolite  Control Women Lactating Women P value 
DMG (μmol/L) 2.5 (2.2, 3.0) 2.4 (2.0, 2.8) 0.5 
Choline (μmol/L) 6.3 (5.9, 6.7) 7.6 (7.1, 8.1) 0.001 
Betaine (μmol/L) 26 (23, 30) 33 (28, 37) 0.03 
PC (μmol/L) 1683 (1592, 1782) 1629 (1545, 1722) 0.4 
SM (μmol/L) 511 (486, 537) 502 (479, 526) 0.6 
1 All values are back transformed predicted means (95% CIs) across the 10 wk study. Data were 
derived by using mixed linear models that tested the effect of reproductive state on the 
dependent variables as described in the main text. Sample size is n=21 for control women; n=27 
for lactating women. Data are not stratified by choline intake because reproductive state and 
choline intake did not interact to affect the dependent variables. DMG, dimethylglycine; PC, 
phosphatidylcholine; SM, sphingomyelin.  
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Urinary choline metabolite excretion  
 Throughout the study period, lactating (versus control) women exhibited decreased 
urinary loss of DMG (p=0.0001) and betaine (p=0.0001) throughout the study period; whereas 
urinary loss of choline was not influenced by reproductive state. Reproductive state did not 
interact with choline intake (P≥0.2) or time (P≥0.3) (see Table 4).  
 
TABLE 4. Effect of reproductive state on urinary choline metabolite across the study period. 1,2 
 
 Metabolite Control Women Lactating Women P value 
DMG (mg/d) 3.9 (3.2, 4.8) 1.6 (1.4, 2)  0.0001 
Choline (mg/d) 2.4 (2.1, 2.7) 2.3 (2.1, 2.7) 0.9 
Betaine (mg/d) 6.8 (5.8, 8) 3.8 (3.2, 4.4)  0.0001 
1 All values are back transformed predicted means (95% CIs) throughout the 10 wk study. Data 
were derived by using mixed linear models that tested the effect of reproductive state on the 
dependent variables as described in the main text. Sample size is n=21 for control women; n=27 
for lactating women. No significant interactions (P>0.05) between reproductive state and 
choline intake or reproductive state and time were detected. DMG, dimethylglycine.  
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Enrichment of plasma choline metabolites  
 At study-end (wk10), labeled choline metabolites were detected at acceptable signal-to-
noise ratios in blood samples including d3-choline, d9-choline, d3-betaine, d9-betaine, d3-DMG, 
d6-DMG, d3-sarcosine, d3-methionine, d3-PC, d6-PC, d9-PC, and d9-SM. Lactating women had 
lower d3-betaine (p=0.05) enrichment than control women (see Table 5). Lactating women also 
had a lower circulating ratio of d3-betaine: d3-choline (p=0.02) versus control women. There 
was no significant interaction between reproductive state and choline intake in any analysis 
undertaken, therefore, women were not stratified by choline intake and reanalyzed.  
 
TABLE 5. Effect of reproductive state on the isotopic enrichment of choline metabolites at study-
end (wk10).1,2 
 
Metabolite  Control Women Lactating Women P value 
Blood Enrichment 
d9-choline  6.6 ± 0.2 6.6 ± 0.2 0.9 
d6-DMG  30 ± 0.8 30 ± 0.8 0.8 
d3-choline  2.0 ± 0.1 1.9 ± 0.1 0.3 
d3-betaine  1.4 ± 0.05 1.3 ± 0.1 0.05 
d3-PC 2.9 ± 0.1 2.7 ± 0.1 0.4 
d6-PC 0.2 ± 0.01 0.2 ± 0.02 0.9 
d9-PC 7.0 ± 0.1 7.0 ± 0.2 0.7 
d9-SM 7.3 ± 0.2 6.9 ± 0.2 0.3 
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d9-betaine 9.5 ± 0.4 8.7 ± 0.5 0.3 
Blood Enrichment Ratios 
d9-betaine : d9-choline  1.3 ± 0.04 1.3 ± 0.04 1 
d9-PC : d9-choline  1.1 ± 0.03 1.0 ± 0.04 0.1 
d9-SM : d9-PC 1 ± 0.009 1 ± 0.01 0.7 
d6-DMG : d9-betaine 3.5 ± 0.1 3.5 ± 0.1 0.8 
d3-sarcosine : d6-DMG 8.4 ± 0.02 0.8 ± 0.02 0.2 
d3+d6-PC : d9-PC 0.4 ± 0.02 0.4 ± 0.02 0.9 
d3-choline : d3-PC  0.7 ± 0.03 0.7 ± 0.03 0.5 
d3-betaine : d3-choline  0.7 ± 0.009 0.7 ± 0.01 0.02 
d9-betaine : d9-PC  1.2 ± 0.05 1.2 ± 0.05 0.3 
d9-betaine:d3-methionine 16 ± 1.5 20 ± 1.5 0.1 
d3-betaine:d3-methionine 2.6 ± 0.2 2.9  ± 0.2 0.6 
d3-sarcosine:d3+d6-PC  8.6 ± 0.3 8.5 ± 0.3 0.8 
d3-methionine:d3+d9-betaine  0.06 ± 0.004 0.05 ± 0.004 0.1 
1 Data are presented as estimated marginal means± SEM; n=21 for control women, n=23 for 
lactating women.  
2 Data were derived by using two factor ANOVA models that tested the effect of reproductive 
state on the dependent variables as described in the main text.  DMG, dimethylglycine; PC, 
phosphatidylcholine; SM, sphingomyelin.  
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Effect of Choline Intake Among Lactating Women on Biomarkers of Choline Metabolism 
Blood leukocyte choline metabolic gene expression   
 At study-end (wk10), choline intake did not influence the expression of ACHE, PEMT, 
PCYT1A, CHDH, and CHRM4 among lactating women (see Table 6). 
 
TABLE 6. Effect of choline intake on mRNA abundance in lactating women randomized to 480 or 
930 mg/d choline intake at study-end (wk10).1,2 
 
Genes 480 mg choline/d 930 mg choline/d P value 
ACHE 1  ±  1.3 1.2  ±  2 0.3 
PEMT 1  ±  1.2 1.5  ±  1.8 0.5 
PCYT1A 1  ±  0.5 1  ±  0.5 0.7 
CHDH 1  ±  0.6 1  ±  0.3 0.6 
CHRM4 1  ±  0.6 1.3  ±  0.9 0.1 
1 Arithmetic mean ± standard deviation; n=12-14 per choline intake group 
2 Data are presented as fold change using the 480 mg choline/d as the reference (e.g. 930 
average value / 480 average value) and were analyzed by 1-factor ANOVA. 
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Mammary epithelium choline metabolic gene expression  
 At study-end (wk10), choline intake did not influence the transcript abundance of the 
mammary epithelium genes among lactating women (see Table 7). 
 
TABLE 7. Effect of choline intake on mRNA abundance in lactating women randomized to 480 or 
930 mg/d choline intake at study-end (wk10).1,2 
 
Genes 480mg choline/d 930mg choline/d P value 
PEMT 1 ± 2.1 0.5 ±  0.4 0.7 
PCYT1A 1 ± 0.5 1.2 ± 0.9 0.6 
CHDH 1 ±  1.0 1.5 ±  1.9 0.6 
1 Arithmetic mean ± standard deviation; n = 13 per choline intake group  
2 Data are presented as fold change using the 480 mg choline/d as the reference (e.g. 930 
average value / 480 average value) and were analyzed by 1-factor ANOVA. 
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Plasma choline metabolite concentrations   
 Throughout the 10 wk study, time did not influence circulating concentrations of choline 
metabolites among lactating women.   However, consumption of 930 (vs. 480) mg choline/d 
yielded higher plasma concentrations of DMG (p=0.02) and betaine (P=0.05). Choline (p=0.3), 
phosphatidylcholine (p=0.5), and sphingomyelin (p=0.8) were unaltered by choline intake (see 
Figure 2). 
 
Urinary choline metabolite excretion  
 Throughout the 10 wk study, neither time or choline intake influenced circulating 
concentrations of the choline metabolites among lactating women (see Figure 3). 
 
Choline-related plasma amino acid concentrations  
 Throughout the 10 wk study, lactating women consuming 930 (vs. 480_ mg choline/d 
exhibited decreased plasma cystathionine (p=0.03) and increased plasma sarcosine (p=0.004) 
across time. Choline intake did not affect plasma glycine (p=0.7), methionine (p=0.5), cysteine 
(p=0.9), or homocysteine (p=0.7) (see Figure 4). Time was not a significant factor although 
borderline decreases were observed in cystathionine (p = 0.07). 
 
Urinary choline-related amino acid excretion  
 Throughout the 10 wk study, lactating women consuming 930 (vs. 480) mg choline/d did 
not exhibit changes in urinary loss of glycine (p=0.9); cystathionine (p=0.7), methionine (p=0.4), 
cysteine (p=0.7), homocysteine (p=0.6), or sarcosine (p=0.8) (see Figure 5).  
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Enrichment of plasma choline metabolites  
  At study-end (wk10), lactating women consuming 930 (vs. 480) mg choline/d had higher 
plasma enrichment of d9-choline (p=0.04); d6-DMG (p=0.03); d3-choline (p=0.001); d3-betaine 
(p=0.0001); d3-sarcosine (p=0.0001); d3-methionine (p=0.01); d3-PC (p=0.001); d6-PC 
(p=0.001); and d9-betaine (p=0.0001) but trended towards lower plasma enrichment of d9-SM 
(p=0.07) (see Table 8). In addition, lactating women consuming 930 (vs. 480) mg choline/d had 
higher circulating ratios of d9-betaine: d9-choline (p=0.05) and d3+d6-PC:d9-PC (p=0.04) but 
lower circulating ratios of d6-DMG:d9-betaine (p=0.001) and d3-sarcosine: d3+d6-PC (p=0.05).  
TABLE 8. Effect of choline intake on blood enrichments, and the enrichment ratios, of choline 
metabolites at study-end (wk10) among lactating women consuming 22% of 480 or 930 mg 
choline/d as methyl-d9-choline from study wk-6 to wk 101,2 
 Metabolite 480 mg choline/d  930 mg choline/d  P value 
Blood Enrichment 
d9-choline  6 ± 0.2 6.9 ± 0.3 0.04 
d6-DMG  27 ± 1.4 32 ± 1.9 0.03 
d3-choline  1.6 ± 0.1 2.2 ± 0.1 0.001 
d3-betaine  1.1 ± 0.04 1.4 ± 0.05 0.0001 
d3-sarcosine 20 ± 0.8 27 ± 1.1 0.0001 
d3-methionine 0.4 ± 0.04 0.6 ± 0.05 0.01 
d3-PC 2.2 ± 0.1 3.2 ± 0.2 0.001 
d6-PC 0.1 ± 0.02 0.2 ± 0.02 0.001 
d9-PC 7 ± 0.1 6.6 ± 0.2 0.1 
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d9-SM 7.1 ± 0.2 6.3 ± 0.3 0.07 
d9-betaine 7.4 ± 0.4 11 ± 0.5 0.0001 
Blood Enrichment Ratios 
d9-betaine : d9-choline  1.2 ± 0.04 1.4 ± 0.05 0.05 
d9-PC : d9-choline  1.1 ± 0.06 1 ± 0.08 0.2 
d9-SM : d9-PC 1 ± 0.02 1 ± 0.02 0.5 
d6-DMG : d9-betaine 3.7 ± 0.1 3.2 ± 0.1 0.001 
d3-sarcosine : d6-DMG 0.8 ± 0.03 0.8 ± 0.04 0.3 
d3+d6-PC : d9-PC 0.4 ± 0.03 0.5 ± 0.04 0.04 
d3-choline : d3-PC  0.7 ± 0.04 0.7 ± 0.05 0.7 
d3-betaine : d3-choline  0.7 ± 0.01 0.7 ± 0.02 1 
d9-betaine : d9-PC  1.2 ± 0.08 1.3 ± 0.1 0.8 
d9-betaine : d3-methionine 21 ± 1.7 19 ± 2.4 0.6 
d3-betaine : d3-methionine 2.8 ± 0.3 3.3 ± 0.5 0.5 
d3-sarcosine : d3+d6-PC  9 ± 0.3 7.8 ± 0.4 0.05 
d3-methionine:d3+d9-betaine  0.05 ± 0.004 0.05 ± 0.005 0.5 
d6-DMG:d9-choline 4.5 (0.2) 4.4 (0.2) 0.8 
1 Data are presented as estimated marginal means± SEM; n=14 for 480 mg choline/d, n=9 for 
930 mg choline/d 
2 Data were derived by using one factor ANOVA models that tested the effect of choline intake 
on the dependent variables as described in the main text.  DMG, dimethylglycine; PC, 
phosphatidylcholine; SM, sphingomyelin.  
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Enrichment of urinary choline metabolites  
 At study-end (wk10), labeled choline metabolites were detected at acceptable signal-to-
noise ratios in urine samples including d3-choline, d9-choline, d3-betaine, d9-betaine, d3-DMG, 
d6-DMG, d3-sarcosine, d3-methionine, and d3-SAM. Lactating women consuming 930 vs. 480 
mg choline/d had greater urine enrichment of all metabolites, with significantly greater 
enrichment of d6-DMG (p=0.0001); d3-choline (p=0.0001); d3-betaine (p=0.0001); d3-DMG 
(p=0.04); and d3-SAM (p=0.0001). Lactating women consuming 930 vs. 480 mg choline/d had a 
lower urinary ratio of d6-DMG:d9-betaine (p= 0.02) and  trended towards a higher circulating 
ratio of d3-betaine:d3-choline (p= 0.06), (see Table 9). 
 
TABLE 9. Effect of choline intake on urinary enrichments of choline metabolites at study-end 
(wk10) among lactating women consuming 22% of 480 or 930 mg choline/d as methyl-d9-
choline from study wk-6 to wk 101,2 
 
Metabolite 480 mg choline/d 930 mg choline/d P value 
d9-choline  10 ± 0.7 12 ± 1 0.4 
d9-betaine 9.5 ± 0.5 11 ± 0.7 0.1 
d6-DMG 30 ± 0.9 37 ± 1.2 0.0001 
d3-choline   1.6 ± 0.03 2 ± 0.04 0.0001 
d3-betaine 1.1 ± 0.03 1.4 ± 0.04 0.0001 
d3-DMG 1 ± 0.05 1.2 ± 0.07 0.04 
d3-sarcosine 17± 1.5 20± 2.2 0.3 
d3-methionine 0.4 ± 0.1 0.4 ± 0.1 0.7 
32 
 
d3-SAM 0.5 ± 0.02 0.7 ± 0.03 0.0001 
Urinary Enrichment Ratios 
d9-betaine : d9-choline  0.9 ± 0.03 0.9 ± 0.03 0.7 
d3-betaine : d3-choline 0.7 ± 0.009  0.7 ± 0.01 0.06 
d6-DMG : d9-betaine  3.5 ± 0.1 3.1 ± 0.1 0.02 
d3-DMG : d3-betaine 0.9 ± 0.03 0.8 ± 0.04 0.2 
d3-methionine : d3+d9-betaine  0.03 ± 0.003 0.03 ± 0.003 0.1 
d3-sarcosine : d3+d6 DMG 0.5 ± 0.04 0.6  ± 0.06 0.2 
d3-SAM: d3-methionine 1.7 ± 0.2 1.6 ± 0.3 0.7 
d3-methionine: d9-betaine 0.03 ± 0.003 0.04 ± 0.004 0.1 
d3-methionine:d3-betaine 0.3 ± 0.04 0.3 ± 0.05 0.9 
1 Data are presented as estimated marginal means± SEM; n=14 for 480 mg choline/d, n=9 for 
930 mg choline/d 
2 Data were derived by using one factor ANOVA models that tested the effect of choline intake 
on the dependent variables as described in the main text.  DMG, dimethylglycine.  
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FIGURE2. Back transformed predicted means (95% CIs) of plasma free choline, betaine, 
dimethylglycine (DMG), phosphatidylcholine (PC), and sphingomyelin (SM) in lactating women 
consuming 480 mg choline/d (n=14) or 930 mg choline/d (n=13) for 10 wk. The plotted data 
were estimated by using mixed linear regression models. Different superscript letters indicate 
that the choline metabolite differed (P≤0.05) between choline-intake groups.  
a 
 
b 
 
a 
 
b 
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 FIGURE 3. Back transformed predicted means (95% CIs) of urinary choline, betaine, and 
dimethylglycine (DMG) in lactating women consuming 480 mg choline/d (n=14) or 930 mg 
choline/d (n=13) for 10 wk. The plotted data were estimated by using mixed linear regression 
models. No metabolites were significantly affected by choline intake among lactating women. 
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FIGURE 4. Back transformed predicted means (95% CIs) of plasma glycine, methionine, 
cystiene, cystathionine, homocysteine, and sarcosine in lactating women consuming 480 mg 
choline/d (n=14) or 930 mg choline/d (n=13) for 10 wk. The plotted data were estimated by 
using mixed linear regression models. Different superscript letters indicate that the choline 
metabolite differed (P≤0.05) between choline-intake groups. 
 
b 
a 
b 
a 
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FIGURE 5. Back transformed predicted means (95% CIs) of urinary glycine, methionine, 
cystiene, cystathionine, homocysteine, and methylglycine in lactating women consuming 480 
mg choline/d (n=14) or 930 mg choline/d (n=12) for 10 wk. The plotted data were estimated by 
using mixed linear regression models. No results were significant. 
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Correlations between mammary epithelium genes and blood leukocyte genes 
 At study-end (wk10), mammary epithelium PEMT (Pearson correlation = 0.371; 
p=0.082), CHDH (Pearson correlation = -0.084; p=0.684), and PCYT1A (Pearson correlation =  
-0.004; p=0.986) expression were not significantly correlated with expression of the same gene 
in plasma leukocytes.  
 
  
38 
 
DISCUSSION  
 This highly controlled feeding study sought to quantify the effects of reproductive state 
and choline intake during lactation on biomarkers of choline metabolism. The following main 
findings emerged: 1) lactation alters biomarkers of choline metabolism and elevates plasma 
betaine and choline; 2) a higher choline intake during lactation increases betaine supply and 
subsequent synthesis of DMG, sarcosine, and PEMT-PC from betaine; and 3) blood leukocyte 
gene expression is not a proxy for mammary epithelium gene expression.  
 
Lactating women exhibit elevations in plasma betaine and choline  
 To the best of our knowledge, this is the first study to report elevated concentrations of 
plasma betaine during human lactation.  Our finding of 27% higher plasma betaine in lactating 
(vs. control) women diverges from the  ~50% lower plasma betaine observed during the latter 
half of pregnancy (Yan et al. 2012; Velzing-Aarts et al., 2005; Friesen et al., 2007). Whereas 
pregnancy increases the use of choline as a methyl donor and leads to diminished 
concentrations of plasma betaine (Yan et al. 2012), lactation appears to conserve betaine 
perhaps because of betaine’s role as an osmolyte (Lever and Slow, 2010; Garrett et al., 2013, 
Rudolf et al., 2007; Suzuki et al., 1993). Betaine plays a central role in maintaining osmotic 
balance and is elevated in mouse lactating mammary gland (Rudolf et al. 2007); is released 
from rat liver upon hypoosmotic stress (Wettstein et al., 1998); and is accumulated in the 
kidney to counter hyperosmotic stress (Rosas-Rodriguez et al., 2010). Thus, the observed 
elevations in maternal circulating betaine in the present study may be a mechanism for 
maintaining osmotic balance amidst large effluxes of water, proteins and metabolites from 
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maternal circulation to breastmilk (Dewey, 2004).  Betaine is particularly well suited as an 
osmolyte during lactation because it is not a major constituent of breastmilk (Sakamoto et al., 
2001) and is normally lost at very low rates in urine, allowing it to remain in plasma and tissues 
(Lever and Slow, 2010).  
The elevations in plasma betaine during lactation may be attributed in part to betaine 
conservation by the kidney.  Lactating (vs. control) women exhibited a 44% decrease in the 
already low rate of urinary betaine loss which diverges from enhanced loss of urinary betaine 
during pregnancy (Yan et al. 2012). Alterations in the abundance of choline metabolizing 
enzymes during lactation may also contribute.  In the present study, lactating (vs. control) 
women exhibited diminished amounts of blood leukocyte mRNA for ACHE (80%) and CHRM4 
(60%), but trended towards having elevated mRNA abundance of CHDH (40%), encoding the 
enzyme required for synthesizing betaine from choline. As increases in mRNA abundance of 
CHDH are associated with greater enzymatic activity (Slow and Garrow, 2006), the observed 
elevation in CHDH transcript levels indicates a preference for betaine synthesis and has been 
reported to occur under conditions of altered osmotic balance (Hoffman et al. 2012). 
 As previously reported (Ilcol et al., 2005), lactating women exhibited higher circulating 
plasma choline (21%) than control women. Greater circulating plasma choline is also observed 
during the second half of pregnancy and appears to arise from enhanced de novo choline 
synthesis through the PEMT pathway (Yan et al., unpublished data), when estrogen is elevated 
(Resseguie et al., 2007). However, estrogen levels drop after parturition through the 
antagonistic activation of prolactin secretion to initiate and sustain lactogenesis (Freeman et al., 
2000). Therefore, in lactation, de novo synthesis may be less significant for meeting choline 
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demand than in pregnancy. Indeed, d3-labeling of choline metabolites (i.e., produced by the 
PEMT pathway) did not differ between lactating and control women in the present study, 
indicating a lack of effect of reproductive state on PEMT activity.  
 
Lactation influences flux through choline metabolic pathways 
 The larger pool sizes of choline (21%) and betaine (27%) in the lactating (vs. control) 
women would be expected to dilute the isotopically labeled choline metabolites.  Therefore, if 
flux through these pathways was similar among lactating and control women, we would expect 
to observe diminished labeling of the choline and betaine pools.  However, with the exception 
of the 1% lower circulating plasma d3-betaine: d3-choline, no differences were detected in the 
isotopic labeling of the plasma choline metabolites.  These data suggest that dietary choline is 
replacing unlabeled choline and betaine at a faster rate in lactating (vs. control) women thereby 
contributing to the larger pool sizes of these metabolites in this reproductive group.   
 
Higher consumption of choline during lactation elevates betaine, DMG, and sarcosine 
 Consumption of 930 vs. 480 mg choline/d by lactating women increased several of the 
oxidative derivatives of choline including plasma betaine (16%), DMG (26%) and sarcosine 
(15%).  Higher circulating concentrations of DMG and sarcosine are indicators of increased 
methyl donor activity and were similarly observed in our pregnant cohort in response to choline 
intakes of 930 vs. 480 mg choline/d (Yan et al., 2012). Notably, higher choline intake did not 
further increase the already elevated concentrations of plasma choline, as no differences were 
detected in this biomarker between the choline intake groups. 
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 Increases in the oxidative products of choline metabolism during lactation may have 
biological implications that extend beyond choline’s role as a methyl donor.  Elevations in 
betaine during lactation may enhance the body’s ability to handle fluid fluctuations due to its 
role as an osmolyte. Therefore, betaine may aid lactating women in providing sufficient water 
for breastmilk synthesis, avoiding the production of high osmolarity breastmilk, which has been 
proposed to contribute to infant morbidity and mortality (Pearson et al., 2013; Mercier et al., 
1986). In addition, dimethylglycine and its metabolite sarcosine can be a source of free glycine 
for breastmilk synthesis. Indeed, breastmilk free glycine was 29% higher (p=0.03) in the 930 (vs. 
480) mg choline/d intake group (based on relative peak intensities as measured by Metabolon 
Inc; Durham, NC).   The improvement in breastmilk glycine supply as a result of greater 
maternal choline intake may be functionally important as free glycine is required for the 
production of glutathione in infants (Friesen et al., 2007; Jackson et al., 1997). Greater 
glutathione synthesis would be expected to improve infant redox status, with downstream 
beneficial effects on health (Ahola et al., 2004, Ahola et al., 2004, Kermorvant-Duchemin et al., 
2006; Back et al., 2005; Zhou et al., 2006), especially in premature infants (Friel et al., 2011). 
 
Choline intake during lactation markedly alters flux through choline metabolic pathways 
 Consumption of 930 vs. 480 mg choline/d during lactation increased the ratio of d9-
betaine:d9-choline which is consistent with enhanced partitioning of dietary choline toward 
betaine synthesis in the higher choline intake group.  In addition, the ratio of d3+d6-PC:d9-PC 
was elevated in the 930 vs. 480 mg choline/d intake group.  Because PC derivatives with d3 or 
d6 labeling are obtained from the de novo PEMT pathway, and d9-PC is derived from the CDP-
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choline pathway, elevations in the d3+d6-PC:d9-PC ratio implies that extra choline enhances de 
novo synthesis of the PC molecule.  This finding, which was also observed in our pregnant 
cohort (West et al. 2013; Yan et al., unpublished data), may be functionally important as PEMT-
PC is enriched in DHA relative to CDP-PC (DeLong et al., 1999). Increased synthesis of PEMT-PC 
may act to provide DHA for breastmilk synthesis and infant consumption. Greater consumption 
of DHA by infants is associated with enhanced brain development (Tanaka et al, 2009), and 
superior cognitive performance (Lassek and Gaulin, 2013).  Finally, we show a decline in plasma 
d6-DMG:d9-betaine at  930 vs 480 mg choline/d that may be indicative of unequal changes in 
the rate of flux between steps in choline metabolism in response to higher choline intakes. To a 
lesser extent, a dilution effect from a greater increase in the DMG pool (by 26%) at higher 
choline intakes versus the betaine pool (by 16%) may also be contributing to the decline in d6-
DMG:d9-betaine. Overall, our product to precursor ratios support increased use of choline for 
methyl donation and the production of metabolites (i.e., DHA-PC and glycine) with important 
roles in infant development.   
 
Peripheral blood leukocytes are not a proxy for mammary epithelium gene expression 
  Peripheral blood leukocyte mRNA abundance is a commonly excepted non-invasive 
proxy for average gene expression within less readily accessible tissues in the body (Crescenti  
et al., 2013; Clelland et al., 2013; Fraenkl et al., 2013). However, we found that expression of 
the choline metabolism genes PEMT, PCYT1A, and CHDH were not correlated between blood 
leukocytes and mammary epithelium. Therefore, the leukocyte does not appear to be a good 
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proxy for mammary epithelium choline metabolic gene expression, perhaps because the 
mammary epithelium is a unique compartment within the lactating woman.  
 
Conclusion  
 Lactation is a unique physiologic state which alters choline metabolism in a manner that 
diverges from that of pregnant and control women.  In particular, lactating women exhibit 
higher circulating concentrations of betaine perhaps because of its role as an osmolyte.  A 
higher choline intake during lactation increases betaine and downstream oxidative products 
which may improve osmotic balance, increase methyl group donation, and enhance breastmilk 
glycine supply.  
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